Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (INM)
Filing Type: Form 8-K (Current Report)
Date of Report: October 13, 2021
Event: Completion of the acquisition of BayMedica, Inc. via an amended and restated agreement and plan of reorganization.
Key Financial Metrics and Transaction Details
This filing reports a material definitive agreement and asset acquisition rather than periodic financial performance. Key transaction metrics include:
- Stock Consideration: 2,050,000 common shares of InMed issued to BayMedica equity and convertible debt holders.
- Cash Consideration: $1,000,000 included in the merger consideration, to be held in escrow at closing.
- Escrow Conditions: Cash consideration is subject to reduction for post-closing adjustments or indemnification claims.
- Registration Rights: InMed agreed to file a resale registration statement within 120 days following the closing.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period, as this is a transactional report.
Material Changes Versus Prior Period
The filing details amendments to the Original Agreement dated September 10, 2021:
- Share Issuance Increase: The number of InMed common shares to be issued increased from 1,780,000 to 2,050,000.
- Warrant Elimination: Series A and Series B Warrants from the Original Agreement were eliminated.
- Cash Addition: $1,000,000 in cash consideration was added to replace the warrants.
Guidance, Outlook, and Risks
Management Commentary: The Company closed the Merger on October 13, 2021, with BayMedica merging into InMed's wholly-owned subsidiary, BayMedica, LLC. A press release was issued on the same date.
Financial Statements: Financial statements of the acquired business and pro forma financial information are not included in this filing. They are scheduled to be filed by amendment within 71 calendar days.
Risks and Contingencies: The $1,000,000 cash consideration is contingent upon post-closing adjustments and the satisfaction of indemnification claims.
Investor Verification Checklist
- Verify the final count of shares issued (2,050,000) and the impact on existing shareholder dilution.
- Monitor the upcoming amendment (within 71 days) for the financial statements of BayMedica and pro forma financial information.
- Confirm the status of the resale registration statement to be filed within 120 days of closing.
- Review the escrow agreement terms regarding the $1,000,000 cash consideration and potential reductions.